MERCK & CO., INC. (NYSE:MRK) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
|
(a)
|
The Annual Meeting of Shareholders of Merck Co., Inc. (the
“Company”) was held on May 23, 2017. |
|
(b)
|
Shareholders voted on the matters set forth below:
|
|
Item 1.
|
All of the following persons nominated were elected to
serve as directors and received the number of votes set forth opposite their respective names: |
|
Names
|
|
Votes
For
|
|
Votes
Against
|
|
Abstentions
|
|
Broker
Non-Votes
|
||||
|
Leslie A. Brun
|
|
1,913,570,500
|
|
|
80,741,934
|
|
|
4,807,908
|
|
|
382,947,240
|
|
|
Thomas R. Cech, Ph.D.
|
|
1,986,322,452
|
|
8,845,888
|
|
3,952,002
|
|
382,947,240
|
||||
|
Pamela J. Craig
|
|
1,988,464,681
|
|
|
6,530,122
|
|
|
4,125,539
|
|
|
382,947,240
|
|
|
Kenneth C. Frazier
|
|
1,906,531,905
|
|
80,110,591
|
|
12,477,846
|
|
382,947,240
|
||||
|
Thomas H. Glocer
|
|
1,978,350,550
|
|
|
16,678,177
|
|
|
4,091,615
|
|
|
382,947,240
|
|
|
Rochelle B. Lazarus
|
|
1,978,253,209
|
|
16,188,730
|
|
4,678,403
|
|
382,947,240
|
||||
|
John H. Noseworthy, M.D.
|
|
1,987,289,303
|
|
|
7,871,409
|
|
|
3,959,630
|
|
|
382,947,240
|
|
|
Carlos E. Represas
|
|
1,977,906,630
|
|
17,156,920
|
|
4,056,792
|
|
382,947,240
|
||||
|
Paul B. Rothman, M.D.
|
|
1,988,103,870
|
|
|
7,111,688
|
|
|
3,904,784
|
|
|
382,947,240
|
|
|
Patricia F. Russo
|
|
1,690,919,415
|
|
303,263,696
|
|
4,937,231
|
|
382,947,240
|
||||
|
Craig B. Thompson, M.D.
|
|
1,986,996,094
|
|
|
8,162,837
|
|
|
3,961,411
|
|
|
382,947,240
|
|
|
Wendell P. Weeks
|
|
1,725,948,887
|
|
269,137,168
|
|
4,034,287
|
|
382,947,240
|
||||
|
Peter C. Wendell
|
|
1,974,632,978
|
|
|
20,421,145
|
|
|
4,066,219
|
|
|
382,947,240
|
|
|
Item 2.
|
A proposal to approve, by non-binding advisory vote, the
compensation of our Named Executive Officers received the following votes: |
|
For
|
|
Against
|
|
Abstained
|
|
Broker
Non-Votes
|
|
|
1,897,185,596
|
|
91,226,313
|
|
10,708,433
|
|
382,947,240
|
|
|
Item 3.
|
A proposal to approve, by non-binding advisory vote, the
frequency of future votes to approve the compensation of our Named Executive Officers received the following votes: |
|
1 Year
|
|
2 Years
|
|
3 Years
|
|
Abstained
|
|
Broker
Non-Votes
|
|
|
1,793,458,522
|
|
7,664,645
|
|
191,679,352
|
|
6,317,823
|
|
382,947,240
|
|
|
Item 4.
|
A proposal to ratify the appointment of
PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2017 received the following votes: |
|
For
|
|
Against
|
|
Abstained
|
|
|
|
|
2,340,354,229
|
|
35,103,594
|
|
6,609,759
|
|
|
|
chairman received the following votes:
|
For
|
|
Against
|
|
Abstained
|
|
Broker
Non-Votes
|
|
|
928,762,128
|
|
1,061,968,067
|
|
8,390,147
|
|
382,947,240
|
|
|
Item 6.
|
A shareholder proposal concerning employee practices in
Israel/Palestine received the following votes: |
|
For
|
|
Against
|
|
Abstained
|
|
Broker
Non-Votes
|
|
|
48,105,678
|
|
1,832,554,849
|
|
118,459,815
|
|
382,947,240
|
|
|
Item 7.
|
A shareholder proposal requesting a report on conducting
business in conflict-affected areas received the following votes: |
|
For
|
|
Against
|
|
Abstained
|
|
Broker
Non-Votes
|
|
|
451,496,451
|
|
1,463,065,062
|
|
84,558,829
|
|
382,947,240
|
|
|
Item 8.
|
A shareholder proposal requesting a report on Board
oversight of product safety and quality received the following votes: |
|
For
|
|
Against
|
|
Abstained
|
|
Broker
Non-Votes
|
|
|
130,790,903
|
|
1,795,383,307
|
|
72,946,132
|
|
382,947,240
|
|
the vote relating to frequency of compensation votes, to be
approved.
|
(d)
|
Based on the voting results set forth in (b) (3) above, the
Company’s Board of Directors has determined that the Company will hold an annual non-binding advisory vote on the compensation of the Named Executive Officers listed in the proxy statement for its Annual Meeting of Shareholders. |
About MERCK & CO., INC. (NYSE:MRK)
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company’s animal health products are sold to veterinarians, distributors and animal producers. MERCK & CO., INC. (NYSE:MRK) Recent Trading Information
MERCK & CO., INC. (NYSE:MRK) closed its last trading session down -0.18 at 64.75 with 7,072,657 shares trading hands.